Obesity Management Guideline Implementation Check List

12 Steps that Define Excellent Care and Continuous and Active Participation

36 months

1.  Weight Classification / Weight Measurement

2.  Determine BMI and remeasure for the duration of the program

Remeasure q 6 months

3.  Determine body weight and waist circumference,

Every other month

4.  Documentation of weight loss pounds/week along with any relevant clinical changes

Every month

Provide documentation of intervention, education (reinforcement) in the areas of:

5.  Nutrition management, caloric distribution, snacking behaviors; in general, average caloric intake[1].  This may include use of alcohol, review of the side effect of medication (Periactin, steroids, insulin and other Rx), etc.

Monthly

6.  Behavioral Modification with emotional management as necessary, with continuity to an appropriate therapist to manage lifestyle changes, stress management and self-image issues.

Monthly for the duration

7.  Efforts towards the prevention of further weight gain and the stabilization of weight, if not gradual weight loss

Monthly

8.  Physical activity[2] and formal and continuous exercise documentation

Monthly

Monitoring changes in key morbidities (clinical risk status)

9A.  Blood pressure[3] management

Monthly

9B.  In those with dyslipidemia,[4], [5] total cholesterol, LDL-cholesterol, and triglycerides, while attempting to raise low levels of HDL-cholesterol

Quarterly, if a problem

9C.  Cigarette Smoking Cessation Programs as Required

Every month

9D.  Impaired Blood Sugars[6]

As necessary, but at least monthly

9E.  Medical Complications of Diabetes

Semi-annually

9F.  Cardiac risk assessment, formal

Men age > 45 years

Women age > 55 years (or postmenopausal)

Semi-annually

10.  Updating Family history[7]

Annually

Pharmacotherapy

11A.  Describe use

Continuously

11B.  Side effects, tolerance

Continuously

11C.  Benefit

Continuously

Formal evaluation for Weight Loss Surgery, if any

12A.  Psychosocial reassessments

Quarterly

12B.  Complete Physical Examination, ROS, Chemical and Clinical Reassessment

Annually


Scope

Weight loss therapy is recommended for patients with a BMI > 30 (See Table I), and for patients with a BMI between 25 and 29.9 with risk factors (See Table 3, below), or a high-risk waist circumference and two or more risk factors (See Tables 2 and 3, below). 

 

 

Goal

To provide criteria and guidelines to achieve the highest likelihood of sustained weight loss[8] and morbidity.

 

 

Objectives

To encourage serious and morbidly obese patients to lose weight and maintain weight loss through conservative measures; to maintain salutary adjustments in their lifestyle choices; and, improve their overall health, thereby.  To ensure that patients who are considered for surgical intervention have been appropriately evaluated and treated and are appropriate selected based upon their risk to benefit ratio.

 

 

Relevance

For the Patient: The quality of life and risk of serious complications, disability and/or death is improved through weight loss in the seriously and/or morbidly obese patient.

For the Health Plan: Health care costs are also reduced as body weight is controlled.

 

 

Extraordinary Considerations

The health care impact of obesity is a complex calculation involving not only direct costs such as end-organ damage, but also indirect costs including pharmaceuticals required, for example, in the management of CAD and hypertension, and increased office visits from injury to weight-bearing joints, strain, cardiac inefficiency, sleep apnea and depression.


 

Steps and Specific Measures

 

 

See the 12 Step “Obesity Management Guideline Implementation Check List,” above for the specific components of this comprehensive and medically supervised weight management program.

 

 

Weight Classification

Table 1

Classifications
BMI (Kg./meter squared)
Underweight <18.5 kg/m sq.
Normal weight 18.5-24.9 kg/m sq.
Overweight 25-29.9 kg/m sq.
Obesity (Class 1) 30-34.9 kg/m sq.
Obesity (Class 2) 35-39.9 kg/m sq.
Extreme obesity (Class 3) > 40 kg/m sq.

 

Weight Gain Management

 

In some patients, weight loss or a reduction in body fat is not achievable.  A goal for these patients should be the prevention of further weight gain.  Prevention of weight gain is also an appropriate goal for people with a BMI of 25 to 29.9 who are not otherwise at high risk.

 

Treatment of the overweight and obese patients is a two-step process: assessment and management.

 

Assessment requires determination of the degree of obesity and the absolute risk status.

 

Management includes the reduction of excess weight and maintenance of this lower body weight, as well as the institution of additional measures to control any associated risk factors.  Strong evidence supports the recommendation that weight loss and weight maintenance programs should employ a combination of low-calorie diets, increased physical activity, and behavior therapy.

 

Therapies

 

A reduction of caloric intake by 500 to 1,000 kcal/day will produce the recommended weight loss of 1 to 2 pounds per week.

 

Physical Activity

 

All adults should set a long-term goal to accumulate at least 30 minutes or more of moderate-intensity physical activity on most, and preferably all, days of the week.

 

 

Pharmacotherapy

 

Pharmacotherapy, approved by the FDA for a long-term treatment, should be used only in the context of a treatment program that includes all the elements described previously: diet, physical activity changes, and behavior therapy; and when lifestyle changes do not promote weight loss after at least six (6) months.  However, Pharmacotherapy is currently limited to those patients who have a BMI > 30, or those who have a BMI > 27 if concomitant obesity-related risk factors or diseases exist.  Not all patients respond to a given drug.  Furthermore, if a patient has not lost 4.4 pounds (2 kg) after 4 weeks, it is not likely that this patient will benefit from the drug.  The decision to add a drug to an obesity treatment program should be made after consideration of all potential risks and benefits and only after all behavioral options have been exhausted.

 

Weight Loss Surgery

 

Although there are risks associated with surgery, it is not yet know whether these risks are greater in the long term than those of any other form of treatment.

 

Special Situations

 

A practitioner can conduct a weight loss and maintenance program without specialization in weight loss management, so long as that person has the requisite interest and knowledge.  Also, nutritionists, registered dietitians, exercise physiologists, nurses, and psychologist offer expertise in dietary counseling, physical activity, and behavior changes and can be used for assessment, treatment, and follow-up during weight loss and weight maintenance.  The relationship between the practitioner and these professionals can be a direct, formal one (as in a “team”), or it may be based on an indirect referral.  A positive, supportive attitude and encouragement from all professionals are crucial to the continuing success of the patient.

 


 

Assessment of Risk Status

Determine the relative risk status based on overweight and obesity parameters. 

In overweight and obese persons weight loss is recommended.  It

  • Lowers elevated blood pressure in those with high blood pressure.
  • Lowers elevated blood glucose levels in those with type 2 diabetes.
  • Therefore, reasonable clinical objectives in managing the risk associated with obesity include:

 

  1. Lowering elevated levels of total cholesterol, LDL-cholesterol, and triglycerides, while raising low levels of HDL-cholesterol in those with dyslipidemia.

 

  1. Table 2 defines relative risk categories according to BMI and waist circumference.  These relate to the need to institute weight loss therapy, but they do not define the required intensity of risk factor modification.  The latter is determined by the estimation of absolute risk based on the presence of associated disease or risk factors.

Table 2

Classification of Overweight and Obesity by BMI, Waist Circumference, and Associated Disease Risk*

 

 

BMI

(kg/m2)

Obesity Class

Disease Risk*

(Relative to Normal Weight and Waist Circumference)

 

 

 

Men < 40 in (< 102 cm)             >40 in (>102 cm)

Women < 35 in (< 88 cm)          >35 in (>88 cm)

Underweight

Normal+

Overweight

Obesity-I

Obesity-II

Extreme Obesity

< 18.5

18.5-24.9

25.0-29.9

30.0-34.9

35.0-39.9

>40

 

 

 

I

II

III

-                                               -

-                                               -

Increased                                  High

High                                         Very High

Very High                                 Very High

Extremely High                         Extremely High

* Disease risk for type 2 diabetes, hypertension, and CVD.

+ Increased waist circumference can also be a marker for increased risk even in persons of normal weight.

Adapted from “Preventing and Managing the Global Epidemic of Obesity, Report of the World Health Organization Consultation of Obesity.” WHO, Geneva, June 1997.

 

  1. Identify patients at very high absolute risk.  Patients with the following diseases have a very high absolute risk that triggers the need for intense risk-factor modification and management of the diseases present:

§         Established coronary heart disease (CHD), including a history of myocardial infarction, angina pectoris (stable or unstable), coronary artery surgery, or coronary artery procedures (e.g., angioplasty).

§         Presence of other atherosclerotic diseases, including peripheral arterial disease, abdominal aortic aneurysm, or symptomatic carotid artery disease.

§         Type 2 diabetes (fasting plasma glucose > 126mg/dL or 2-h postprandial plasma glucose > 200 mg/dL) is a major risk factor for CVD.  Its presence alone places a patient in the category of very high absolute risk.

§         Sleep apnea.  Symptoms and signs include very loud snoring or cessation of breathing during sleep, which is often followed by a loud clearing breath, then brief awakening.

 

  1. Identify other obesity-associated diseases.  Obese patients are at increased risk for several conditions that require detection and appropriate management, but that generally do not lead to widespread or life-threatening consequences.  These include gynecological abnormalities (e.g., menorrhagia, amenorrhea), osteoarthritis, gallstones and their complications, and stress incontinence.  Although obese patients are at increased risk for gallstones, the risk of this disease increased during periods of rapid weight reduction.

 

  1. Identify cardiovascular risk factors that impart a high absolute risk.  Patients can be classified as being at high absolute risk for obesity-related disorders if they have three or more of the multiple risk factors listed in Table 3, below.  The presence of high absolute risk increases the attention paid to cholesterol-lowering therapy and blood pressure management.

 

  1. Other risk factors deserve special consideration because their presence heightens the need for weight reduction in obese persons.

Table 3 Risk Factors

Cigarette Smoking

Hypertension (systolic blood pressure of > 140 mm Hg or diastolic blood pressure > 90 mm Hg) or current use of antihypertensive agents.

High-risk low-density lipoprotein (LDL) cholesterol (serum concentration > 160 mg/dL).  A borderline high-risk LDL-cholesterol (130 to 159 mg/dL) plus two or more other risk factors also confers high risk.

Low high-density lipoprotein (HDL) cholesterol (serum concentration < 35 mg/dL).

Impaired fasting glucose (IFG) (fasting plasma glucose between 110 and 125 mg/dL).  IFG is considered by many authorities to be an independent risk factor for cardiovascular (macrovascular) disease, thus justifying its inclusion among risk factors contributing to high absolute risk.  IFG is well established as a risk factor for type 2 diabetes.

Family history of premature CHD (myocardial infarction or sudden death experienced by the father or other male first-degree relative at or before 55 years of age or other female first-degree relative at or before 65 years of age).

Age > 45 years for men or age > 55 years for women (or postmenopausal).

 

 

 

 

 

 

 

 

Documentation and References

Excerpted from “The Practical Guide Identification, Evaluation, and Treatment of Overweight and Obesity Adults” by the National Institutes of Health, National Heart, Lung, and Blood Institute, NHLBI Obesity Education Initiative, and the North American Association for the Study of Obesity.  NIH Publication Number 00-4084  October 2000



[1]  Goal: average caloric intake by 500 to 1,000 kcal

[2]  Goal for physical activity: 30 minutes or more of moderate-intensity on most, and preferably all, days of the week.

[3]  Hypertension (systolic blood pressure of > 140 mm Hg or diastolic blood pressure > 90 mm Hg) or current use of antihypertensive agents

[4]  High-risk low-density lipoprotein (LDL) cholesterol (serum concentration > 160 mg/dL).  A borderline high-risk LDL-cholesterol (130 to 159 mg/dL) plus two or more other risk factors also confers high risk.

[5]  Low high-density lipoprotein (HDL) cholesterol (serum concentration < 35 mg/dL).

[6]  Impaired fasting glucose (IFG) (fasting plasma glucose between 110 and 125 mg/dL).  IFG is considered by many authorities to be an independent risk factor for cardiovascular (macrovascular) disease, thus justifying its inclusion among risk factors contributing to high absolute risk.  IFG is well established as a risk factor for type 2 diabetes.

[7]  Family history of premature CHD (myocardial infarction or sudden death experienced by the father or other male first-degree relative at or before 55 years of age or other female first-degree relative at or before 65 years of age).

[8]  10% or less, measurable weight loss qualifies